Drug Trial Radar · NCT06306872
A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules
Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Feb 23, 2024
Primary completion
Sep 30, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of which is to evaluate the relative bioavailability and PK characteristics of new and old ABSK-011 capsules in a single oral dose
Conditions
- Healthy Subjects
Interventions
Sequence A ABSK-011Drug
Subjects in sequence A will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
Sequence B ABSK-011Drug
Subjects in sequence A will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: From pre-dose up to 72 hours post-dose. assessed up to 12 months
- AUCTime frame: From pre-dose up to 72 hours post-dose. assessed up to 12 months
- tmaxTime frame: From pre-dose up to 72 hours post-dose. assessed up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.